DECN- "Diabetes is a modern day pandemic fueled by the increasing growth of obesity throughout developed countries. With the global market for diabetes therapeutics and diagnostics expected to reach a staggering $157 billion by 2017 and growing 25% annually, smaller sub-markets such as glucose monitoring and diabetes management have grown accordingly ($10 billion in the U.S. for 2015). Companies such as J&J (NYSE:JNJ), Roche (OTCQX:RHHBY), Abbott (NYSE:ABT) and Bayer (OTCPK:BAYRY) have dominated this sub-industry for years, taking a lion's share of the revenues and immense profits year over year. Despite shifts in government and third-party reimbursement negatively impacting the margins of blood glucose strips, their market dominance has continued in no small part due to their teams pressing litigation of their patents. Where in essence, a near insurmountable barrier to entry existed with companies such as J&J suing small players attempting to enter this lucrative business into oblivion."

DECN doesn't need to capture very much of the market before the current market cap becomes laughable.